prescribed drug working needs adjustment ldl cholesterol recognized biomarker heart disease risk food drug administration clinical trials drug lowers cholesterol approval despite existing tests diagnostic prognostic biomarkers patients u.s. tested confirmatory tests cost access restrictions payers including medicare not cover amyloid pet scans based perception definitive diagnosis little clinical value recent studies value pet beta amyloid brain scans supported centers medicare medicaid services shown practicing dementia expert doctors misdiagnose alzheimer 50 percent cases change management treatment patients nearly 70 percent time test inexpensive blood test covered insurance performed clinical setting big impact patients caregivers recently fda issued guidelines recognizing important